Seres Therapeutics Reports Second Quarter 2015 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Seres Therapeutics (MCRB) Posts Q2 Loss of $1.45/Share
August 6, 2015 7:38 AM EDTSeres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($1.45), $1.15 worse than the analyst estimate of ($0.30).
For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.
... More